ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Photys Therapeutics has debuted with $75 million in series A financing to develop phosphorylation-inducing chimeric small molecules (PHICs) to treat disease. PHICs are two-ended molecules that draw together kinases with proteins that are implicated in disease; the kinases phosphorylate the target proteins to modulate their function. The start-up was cofounded by Amit Choudhary of Brigham and Women’s Hospital and the Broad Institute of MIT and Harvard.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter